TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Body Shadow in Improving Virtual Reality Rehabilitation: Preliminary Data From BTS Nirvana
Brief Summary: Purpose of the article: aim of the present study was to detect the differences between the presence or not of body shadows during a virtual reality (VR) training with BTS NIRVANA (BTsN). Materials and methods: In this pilot study, we enrolled 20 post-stroke rehabilitation inpatients, who underwent a neurocognitive-rehabilitative training consisting of 24 sessions (three times a week for 8 weeks) of BTsN. All the patients were randomized into two groups: Semi-immersive virtual training with (S-IVTSgroup) or without (S-IVTgroup) body shadows.

Each participant was evaluated before (T0), and immediately (T1) after the end of the training by a skilled neuropsychologist through the administration of a complete battery, and by a skilled neurologist to assess motor functions.


Options:
A: Arm Label: Robot group; Type: EXPERIMENTAL; Interventions: Device: robot-assisted neurocognitive therapy of hand function | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional neurocognitive rehabilitation | Intervention Type: DEVICE; Name: robot-assisted neurocognitive therapy of hand function; Assigned to Arm(s): Robot group | Intervention Type: OTHER; Name: Conventional neurocognitive rehabilitation; Assigned to Arm(s): Control group
B: Arm Label: Cognitive training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Arm Label: Aerobic exercise training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise training | Arm Label: Sequential training group; Type: EXPERIMENTAL; Interventions: Behavioral: Sequential combination of aerobic exercise and cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Cognitive training group | Intervention Type: BEHAVIORAL; Name: Aerobic exercise training; Assigned to Arm(s): Aerobic exercise training group | Intervention Type: BEHAVIORAL; Name: Sequential combination of aerobic exercise and cognitive training; Assigned to Arm(s): Sequential training group
C: Arm Label: Semi-immersive virtual training with shadow (S-IVTS); Type: EXPERIMENTAL; Interventions: Device: NIRVANA | Arm Label: Semi-immersive virtual training without shadow (S-IVT); Type: EXPERIMENTAL; Interventions: Device: NIRVANA | Intervention Type: DEVICE; Name: NIRVANA; Assigned to Arm(s): Semi-immersive virtual training with shadow (S-IVTS), Semi-immersive virtual training without shadow (S-IVT)
D: Arm Label: Robotic Treatment plus VR; Type: EXPERIMENTAL; Interventions: Device: Robotic Treatment plus VR | Arm Label: Robotic treatment without VR; Type: ACTIVE_COMPARATOR; Interventions: Device: Robotic Treatment plus VR | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Robotic Treatment plus VR | Intervention Type: DEVICE; Name: Robotic Treatment plus VR; Assigned to Arm(s): Conventional treatment, Robotic Treatment plus VR, Robotic treatment without VR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study
Brief Summary: This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb) to placebo for L braziliensis in Bolivia.


Options:
A: Arm Label: Single dose of Pentamidine; Type: EXPERIMENTAL; Interventions: Drug: Single dose of Pentamidine | Arm Label: Two doses of Pentamidine; Type: EXPERIMENTAL; Interventions: Drug: Two doses of Pentamidine | Arm Label: Three doses of Pentamidine; Type: EXPERIMENTAL; Interventions: Drug: Three doses of Pentamidine | Intervention Type: DRUG; Name: Single dose of Pentamidine; Assigned to Arm(s): Single dose of Pentamidine | Intervention Type: DRUG; Name: Two doses of Pentamidine; Assigned to Arm(s): Two doses of Pentamidine | Intervention Type: DRUG; Name: Three doses of Pentamidine; Assigned to Arm(s): Three doses of Pentamidine
B: Arm Label: Liposomal Amphotericin; Type: EXPERIMENTAL; Interventions: Drug: Liposomal Amphotericin B | Intervention Type: DRUG; Name: Liposomal Amphotericin B; Assigned to Arm(s): Liposomal Amphotericin
C: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment
D: Arm Label: Group 1 - Paromomycin cream; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Sulfate | Arm Label: Group 2. Local Injectable Pentamidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentamidine Isethionate | Arm Label: Group 3. Vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Paromomycin Sulfate; Assigned to Arm(s): Group 1 - Paromomycin cream | Intervention Type: DRUG; Name: Pentamidine Isethionate; Assigned to Arm(s): Group 2. Local Injectable Pentamidine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 3. Vehicle control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
Brief Summary: The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Methylene Blue; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): N/A
D: Arm Label: Esketamine + Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Other: Standard of Care | Arm Label: Placebo + Standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of Care | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine + Standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Standard of care | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Esketamine + Standard of care, Placebo + Standard of care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
Brief Summary: The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.


Options:
A: Arm Label: Esketamine + Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Other: Standard of Care | Arm Label: Placebo + Standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of Care | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine + Standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Standard of care | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Esketamine + Standard of care, Placebo + Standard of care
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4995819 15 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 30 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 5 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 15 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 30 mg
C: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4917523 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4917523 0.5 mg | Arm Label: RO4917523 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4917523 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4917523 0.5 mg; Assigned to Arm(s): RO4917523 0.5 mg | Intervention Type: DRUG; Name: RO4917523 1.5 mg; Assigned to Arm(s): RO4917523 1.5 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Brief Summary: Determine the effectiveness of lavender and chamomile aromatherapy of mitigation of symptoms of Neonatal Abstinence Syndrome


Options:
A: Arm Label: Standard therapy plus Aromatherapy; Type: EXPERIMENTAL; Interventions: Drug: lavender and chamomile essential oils | Arm Label: Standard therapy ALONE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lavender and chamomile essential oils; Assigned to Arm(s): Standard therapy plus Aromatherapy
B: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Clonidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clonidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine
C: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone
D: Arm Label: Clonidine; Type: EXPERIMENTAL; Interventions: Drug: Clonidine | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Morphine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Brief Summary: Determine the effectiveness of lavender and chamomile aromatherapy of mitigation of symptoms of Neonatal Abstinence Syndrome


Options:
A: Arm Label: Oral morphine solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral morphine solution | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine | Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oral morphine solution; Assigned to Arm(s): Oral morphine solution
B: Arm Label: Methadone; Type: N/A; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone
C: Arm Label: sublingual buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: sublingual buprenorphine | Arm Label: oral morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral morphine | Intervention Type: DRUG; Name: sublingual buprenorphine; Assigned to Arm(s): sublingual buprenorphine | Intervention Type: DRUG; Name: oral morphine; Assigned to Arm(s): oral morphine
D: Arm Label: Standard therapy plus Aromatherapy; Type: EXPERIMENTAL; Interventions: Drug: lavender and chamomile essential oils | Arm Label: Standard therapy ALONE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lavender and chamomile essential oils; Assigned to Arm(s): Standard therapy plus Aromatherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Brief Summary: Determine the effectiveness of lavender and chamomile aromatherapy of mitigation of symptoms of Neonatal Abstinence Syndrome


Options:
A: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula
B: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A
C: Arm Label: Standard therapy plus Aromatherapy; Type: EXPERIMENTAL; Interventions: Drug: lavender and chamomile essential oils | Arm Label: Standard therapy ALONE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lavender and chamomile essential oils; Assigned to Arm(s): Standard therapy plus Aromatherapy
D: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women - a Randomized Controlled Study
Brief Summary: The purpose of this study is to determine whether a comprehensive treatment programme for self-management of mixed and urgency urinary incontinence via a mobile app is effective.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2
B: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
C: Arm Label: Tät®II Treatment app; Type: EXPERIMENTAL; Interventions: Device: Tät®II Treatment app | Arm Label: Tät®II Information app; Type: OTHER; Interventions: Device: Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Information app; Assigned to Arm(s): Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Treatment app; Assigned to Arm(s): Tät®II Treatment app
D: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women - a Randomized Controlled Study
Brief Summary: The purpose of this study is to determine whether a comprehensive treatment programme for self-management of mixed and urgency urinary incontinence via a mobile app is effective.


Options:
A: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise classes with pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise classes with pelvic floor muscle training; Assigned to Arm(s): Exercise group
B: Arm Label: Tät®II Treatment app; Type: EXPERIMENTAL; Interventions: Device: Tät®II Treatment app | Arm Label: Tät®II Information app; Type: OTHER; Interventions: Device: Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Information app; Assigned to Arm(s): Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Treatment app; Assigned to Arm(s): Tät®II Treatment app
C: Arm Label: MyHealthebladder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MyHealtheBladder | Arm Label: VA Video Connect; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: VA Video Connect | Intervention Type: BEHAVIORAL; Name: VA Video Connect; Assigned to Arm(s): VA Video Connect | Intervention Type: BEHAVIORAL; Name: MyHealtheBladder; Assigned to Arm(s): MyHealthebladder
D: Arm Label: Drug Therapy Aone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release, individually-titrated | Arm Label: Drug Therapy + Behavioral Training; Type: EXPERIMENTAL; Interventions: Drug: Oxybutynin chloride, extended-release, individually-titrated, Behavioral: Behavior Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release, individually-titrated; Assigned to Arm(s): Drug Therapy + Behavioral Training, Drug Therapy Aone | Intervention Type: BEHAVIORAL; Name: Behavior Training; Assigned to Arm(s): Drug Therapy + Behavioral Training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Noninvasive Ventilation for Preterm Neonates With Respiratory Distress Syndrome: a Multi-center Randomized Controlled Trial
Brief Summary: The investigators compared advantages and disadvantages of two forms of noninvasive respiratory support -noninvasive high-frequency oscillatory ventilation (nHFOV) or nasal continuous positive airway pressure (nCPAP) -as a primary mode of ventilation in premature infants with RDS．


Options:
A: Arm Label: nHFPV; Type: EXPERIMENTAL; Interventions: Procedure: Intrapulmonary Percussive Ventilation | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasal Continuous Positive Airway Pressure ventilation | Intervention Type: PROCEDURE; Name: Nasal Continuous Positive Airway Pressure ventilation; Assigned to Arm(s): nCPAP | Intervention Type: PROCEDURE; Name: Intrapulmonary Percussive Ventilation; Assigned to Arm(s): nHFPV
B: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): NIPPV
C: Arm Label: BP-NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: BP-NCPAP | Arm Label: NIHFV; Type: EXPERIMENTAL; Interventions: Device: NIHFV | Intervention Type: DEVICE; Name: BP-NCPAP; Assigned to Arm(s): BP-NCPAP | Intervention Type: DEVICE; Name: NIHFV; Assigned to Arm(s): NIHFV
D: Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: nasal continuous positive airway pressure (nCPAP) | Arm Label: nHFOV; Type: EXPERIMENTAL; Interventions: Procedure: noninvasive high-frequency ventilation (nHFOV) | Intervention Type: PROCEDURE; Name: noninvasive high-frequency ventilation (nHFOV); Assigned to Arm(s): nHFOV | Intervention Type: PROCEDURE; Name: nasal continuous positive airway pressure (nCPAP); Assigned to Arm(s): nCPAP

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin Versus Low-molecular-weight Heparin (LMWH) and Aspirin in Women With Antiphospholipid Syndrome and Pregnancy Loss
Brief Summary: The APPLE pilot trial is a feasibility study that is a multicentre, open-label, randomized controlled trial. Pregnant women with antiphospholipid syndrome (APS) and a history of late (≥10 weeks gestation) or recurrent early (2 \<10 weeks) pregnancy loss will be recruited.

Eligible and consenting subjects will be assigned to one of two study arms: open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin (ASA) daily until delivery, or open-label low-dose aspirin daily from randomization until delivery.


Options:
A: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
B: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted
C: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
D: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin

Answer: C